Alexion

Alexion bags option on Stealth's phase 3 rare disease drug
Fierce Biotech
Thu, 10/10/19 - 07:58 pm
Alexion
Stealth BioTherapeutics
clinical trials
mitochondrial myopathy
elamipretide
UCB strikes $2.5B deal to buy Ra for rival to Alexion's Soliris
Fierce Biotech
Thu, 10/10/19 - 12:56 pm
UCB Pharma
Ra Pharmaceuticals
M&A
zilucoplan
Alexion
Soliris
Patent Challenge to Alexion Proceeds, But No Amgen Biosimilar Yet
Xconomy
Sat, 08/31/19 - 08:00 pm
patents
Alexion
Amgen
biosimilars
USPTO
Alexion shares slide on Amgen patent challenge to top-seller
Biopharma Dive
Fri, 08/30/19 - 01:00 pm
Amgen
Alexion
inter partes review
patents
Soliris
Should Amgen Finally Buy Alexion Pharmaceuticals?
Yahoo/Motley Fool
Sun, 08/25/19 - 05:00 pm
Amgen
Alexion
M&A
Why Alexion Makes Sense As A Target, But Amgen Doesn't As A Buyer
Investors Business Daily
Sat, 08/24/19 - 11:14 am
Amgen
Alexion
M&A
3 Reasons Why Amgen Could Actually Acquire Alexion
Motley Fool
Sat, 08/24/19 - 11:10 am
Alexion
Amgen
M&A
Alexion's beating forecasts with Soliris-to-Ultomiris switch. So what's up with its pesky stock price?
Fierce Pharma
Fri, 07/26/19 - 11:05 am
Alexion
Soliris
Ultomiris
PNH
Alexion’s Soliris follow-up Ultomiris snares EU approval
Pharmaforum
Sun, 07/7/19 - 11:13 am
Alexion
Europe
Ultomiris
Soliris
patents
PNH
Alexion's cash cow Soliris just got fatter as FDA greenlights another blockbuster indication
Endpoints
Fri, 06/28/19 - 12:36 pm
Alexion
Soliris
FDA
autoimmune disease
NMOSD
FDA Action Alert: Regeneron, Sanofi, Celgene
BioSpace
Mon, 06/24/19 - 07:27 pm
FDA
drug approvals
Acer Therapeutics
Edsivo
Regeneron
Sanofi
Dupixent
Celgene
Revlimid
Alexion
Soliris
Dova Pharmaceuticals
Doptelet
Nabriva Therapeutics
Contepo
Retrophin
Thiola
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/23/19 - 02:04 pm
Merck
Keytruda
Melinta Therapeutics
Amag Pharmaceuticals
Palatin
Acer Therapeutics
Sanofi
Regeneron
Alexion
Pfizer
Roche
Navidea Biopharmaceuticals
Ascendis Pharma
Scholar Rock
Adaptive Biotechnologies
BridgeBio
IPOs
G Medical Innovations
Karuna
Morphic Therapeutics
3 Big Biotechs Hold Growth Potential in Second Half of 2019
Yahoo/Zacks.com
Sat, 06/22/19 - 12:27 pm
Alexion
Gilead Sciences
Vertex Pharmaceuticals
FDA fast-tracks Alexion's Ultomiris in 2nd Soliris indication
Fierce Pharma
Fri, 06/21/19 - 11:40 pm
Alexion
Ultomiris
FDA
atypical hemolytic uremic syndrome
Mark Your Calendar For These June PDUFA Dates
Yahoo/Benzinga
Sat, 06/1/19 - 12:52 pm
FDA
Merck
Zerbaxa
XERIS
Gvoke HypoPen
Keytruda
Amag Pharmaceuticals
Palatin
Vyleesi
Acer Therapeutics
Edsivo
Sanofi
Regeneron
Dupixent
Alexion
Soliris
Retrophin
Thiola
Allergan
Botox
Go or no go? Merck, Regeneron and Alexion await US expansion
EP Vantage
Thu, 05/30/19 - 09:39 am
Merck
Keytruda
Sanofi
Regeneron
Dupixent
Alexion
Soliris
FDA
Dova Pharmaceuticals
Retrophin
Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big
Motley Fool
Sun, 05/19/19 - 04:05 pm
Alexion
Ultomiris
AbbVie
Upadacitinib
risankizumab
Aimmune Therapeutics
AR-101
Bluebird Bio
LentiGlobin
Alexion gets off to the races with key Ultomiris, Soliris launches
Fierce Pharma
Mon, 04/29/19 - 10:25 am
Alexion
Ultomiris
Soliris
drug launches
The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs
Yahoo/Benzinga
Mon, 04/22/19 - 10:34 am
Concert Pharmaceuticals
Horizon Pharma
Edwards Lifesciences
Zimmer Biomet
Genfit
Precision Biosciences
Boston Scientific
AbbVie
Alexion
Bristol-Myers Squibb
Baxter
Biomarin
AtriCure
Biogen
Seattle Genetics
IPOs
earnings
Big Pharma come together for better drug side effect detection
Pharma Times
Sun, 04/7/19 - 05:18 pm
side effects
adverse events
Pfizer
Roche
Takeda
Eli Lilly
Bristol-Myers Squibb
Gilead Sciences
Alexion
Celgene
International Working Group on Signal Detection and Management in Pharmacovigilance
pharmacovigilance

Pages